Loading
A phase 2 trial of XNW5004 in follicular lymphoma, run by Evopoint Biosciences Inc., now recruiting.
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT07545603 by Evopoint Biosciences Inc., with 65 participants planned, started 2026-02-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: XNW5004 tablets. Conditions listed: Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares XNW5004, Evopoint Biosciences.
Shares XNW5004, Evopoint Biosciences.
Shares XNW5004, Evopoint Biosciences.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/